Consun Pharmaceutical Group Ltd
HKEX:1681
Intrinsic Value
Consun Pharmaceutical Group Ltd. is an investment holding company, which engages in the manufacturing and sales of pharmaceutical products. [ Read More ]
The intrinsic value of one
Consun Pharmaceutical Group Ltd
stock under the Base Case scenario is
13.08
HKD.
Compared to the current market price of 5.58 HKD,
Consun Pharmaceutical Group Ltd
is
Undervalued by 57%.
Consun Pharmaceutical Group Ltd could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Consun Pharmaceutical Group Ltd's market capitalization is 4.5B HKD.
Consun Pharmaceutical Group Ltd stock price is 5.58 HKD.
Consun Pharmaceutical Group Ltd stock price (5.58 HKD) is 57% less than its Intrinsic Value (13.08 HKD).
Consun Pharmaceutical Group Ltd stock price (5.58 HKD) is 72% less than its DCF Value (20.14 HKD). Open DCF Valuation
Consun Pharmaceutical Group Ltd stock price (5.58 HKD) is 7% less than its Relative Value (6.02 HKD). Open Relative Valuation
Consun Pharmaceutical Group Ltd has upside potential of 74% compared to the average analyst price target.
Open Wall St Estimates
Consun Pharmaceutical Group Ltd's ROE (Return on Equity) has decreased in the last 3 years from 24% to 23%.
Consun Pharmaceutical Group Ltd's Revenue has grown by 11% over the past 12 months.
Consun Pharmaceutical Group Ltd's Revenue is forecast to grow at a rate of 10% per year over the next 3 years.
Consun Pharmaceutical Group Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 23%.
Consun Pharmaceutical Group Ltd's Revenue has been growing by 14% per year for the last 3 years.
Consun Pharmaceutical Group Ltd has positive Net Income for the last twelve months.
Consun Pharmaceutical Group Ltd's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 21% to 58%.
Consun Pharmaceutical Group Ltd has positive Operating Income for the last twelve months.
Consun Pharmaceutical Group Ltd's Altman Z-Score is very high and is equal to 3.08.
Consun Pharmaceutical Group Ltd has positive three-year average ROE (Return on Equity): 24%. The company is efficient at transforming stockholders' equity into net income.
Consun Pharmaceutical Group Ltd's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 58%.
Consun Pharmaceutical Group Ltd has positive Gross Profit for the last twelve months.
Consun Pharmaceutical Group Ltd has very high three-year average ROIC (Return on Invested Capital): 34%. The company is very efficient at using invested capital to generate operating income.
Consun Pharmaceutical Group Ltd's short-term assets (4B CNY) exceed its short-term liabilties (1B CNY).
Consun Pharmaceutical Group Ltd's long-term assets (6B CNY) exceed its long-term liabilties (2B CNY).
Consun Pharmaceutical Group Ltd has positive Free Cash Flow for the last twelve months.
Consun Pharmaceutical Group Ltd's D/E (Debt to Equity) is very low and is equal to 0.14.
Consun Pharmaceutical Group Ltd has negative Net Debt. This means that the company has more cash and short-term investments (4B CNY) than debt (507m CNY).
Consun Pharmaceutical Group Ltd earns more than enough operating income (886m CNY) to safely cover interest payments on its debt (14m CNY).
Valuation Backtest
Consun Pharmaceutical Group Ltd
Run backtest to discover the historical profit from buying and selling
Consun Pharmaceutical Group Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Consun Pharmaceutical Group Ltd
Balance Sheet Decomposition
Consun Pharmaceutical Group Ltd
| Current Assets | 4.3B |
| Cash & Short-Term Investments | 3.6B |
| Receivables | 310m |
| Other Current Assets | 384.9m |
| Non-Current Assets | 1.2B |
| Long-Term Investments | 23.9m |
| PP&E | 739.1m |
| Intangibles | 283.1m |
| Other Non-Current Assets | 183.9m |
| Current Liabilities | 1.5B |
| Accounts Payable | 942.4m |
| Short-Term Debt | 503.4m |
| Other Current Liabilities | 49.1m |
| Non-Current Liabilities | 386.5m |
| Long-Term Debt | 3.9m |
| Other Non-Current Liabilities | 382.6m |
Earnings Waterfall
Consun Pharmaceutical Group Ltd
|
Revenue
|
2.6B
CNY
|
|
Cost of Revenue
|
-668.4m
CNY
|
|
Gross Profit
|
1.9B
CNY
|
|
Operating Expenses
|
-1B
CNY
|
|
Operating Income
|
885.8m
CNY
|
|
Other Expenses
|
-101.3m
CNY
|
|
Net Income
|
784.5m
CNY
|
Free Cash Flow Analysis
Consun Pharmaceutical Group Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Consun Pharmaceutical Group Ltd's profitability score is 77/100. The higher the profitability score, the more profitable the company is.
Score
Consun Pharmaceutical Group Ltd's profitability score is 77/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Consun Pharmaceutical Group Ltd's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Score
Consun Pharmaceutical Group Ltd's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Consun Pharmaceutical Group Ltd
According to Wall Street analysts, the average 1-year price target for
Consun Pharmaceutical Group Ltd
is 9.69 HKD
with a low forecast of 7.17 HKD and a high forecast of 12.5 HKD.
Shareholder Return
Price
Consun Pharmaceutical Group Ltd
| Average Annual Return | 4.07% |
| Standard Deviation of Annual Returns | 35.61% |
| Max Drawdown | -45% |
| Market Capitalization | 4.5B HKD |
| Shares Outstanding | 819 625 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Consun Pharmaceutical Group Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Consun Pharmaceutical Group Ltd. is an investment holding company, which engages in the manufacturing and sales of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2013-12-19. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.
Contact
IPO
Employees
Officers
The intrinsic value of one
Consun Pharmaceutical Group Ltd
stock under the Base Case scenario is
13.08
HKD.
Compared to the current market price of 5.58 HKD,
Consun Pharmaceutical Group Ltd
is
Undervalued by 57%.
You don't have any saved screeners yet
